Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected RCC Receiving Immunotherapy (SAMURAI)

Details

The Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) trial compares standard immunotherapy to immunotherapy combined with radiation for patients not suited for surgery. It's an open-label trial, meaning participants and doctors know the treatments. After treatment, patients are closely monitore...